```json
{
  "entities": [
    {
      "type": "Microbe",
      "name": "Clostridium difficile"
    },
    {
      "type": "Microbe",
      "name": "NAP1/BI/027"
    },
    {
      "type": "Microbe",
      "name": "Clostridium difficile infection"
    },
    {
      "type": "Microbe",
      "name": "CDI"
    },
    {
      "type": "Microbe",
      "name": "Clostridium difficile infection (CDI)"
    },
    {
      "type": "Microbe",
      "name": "Clostridium difficile infection cases"
    },
    {
      "type": "Microbe",
      "name": "Clostridium difficile isolates"
    },
    {
      "type": "Microbe",
      "name": "NAP1/BI/027 strain"
    },
    {
      "type": "Microbe",
      "name": "non-NAP1/BI/027 strain"
    },
    {
      "type": "Microbe",
      "name": "strain typing results"
    },
    {
      "type": "Microbe",
      "name": "strain typing"
    },
    {
      "type": "Microbe",
      "name": "typing"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "course of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "vancomycin"
    },
    {
      "type": "Microbe",
      "name": "third-party payer"
    },
    {
      "type": "Microbe",
      "name": "economic analysis"
    },
    {
      "type": "Microbe",
      "name": "decision analytic simulation model"
    },
    {
      "type": "Microbe",
      "name": "incremental cost-effectiveness ratio"
    },
    {
      "type": "Microbe",
      "name": "quality-adjusted life-year"
    },
    {
      "type": "Microbe",
      "name": "cost-effectiveness"
    },
    {
      "type": "Microbe",
      "name": "cost"
    },
    {
      "type": "Microbe",
      "name": "economic value"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomicin based on strain typing results"
    },
    {
      "type": "Microbe",
      "name": "dominated"
    },
    {
      "type": "Microbe",
      "name": "more costly and less effective"
    },
    {
      "type": "Microbe",
      "name": "lower costs"
    },
    {
      "type": "Microbe",
      "name": "approximately 50%"
    },
    {
      "type": "Microbe",
      "name": "is"
    },
    {
      "type": "Microbe",
      "name": "accounting"
    },
    {
      "type": "Microbe",
      "name": "approximately 50% of isolates"
    },
    {
      "type": "Microbe",
      "name": "using fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "first-line treatment for CDI"
    },
    {
      "type": "Microbe",
      "name": "cost-effective"
    },
    {
      "type": "Microbe",
      "name": "typing and treatment with fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "based on strain"
    },
    {
      "type": "Microbe",
      "name": "depending on the costs of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "economic value of fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment strategies"
    },
    {
      "type": "Microbe",
      "name": "treatment strategy"
    },
    {
      "type": "Microbe",
      "name": "treatment"
    },
    {
      "type": "Microbe",
      "name": "treatment of CDI"
    },
    {
      "type": "Microbe",
      "name": "treatment of all CDI cases"
    },
    {
      "type": "Microbe",
      "name": "treatment based on strain typing"
    },
    {
      "type": "Microbe",
      "name": "Food and Drug Administration"
    },
    {
      "type": "Microbe",
      "name": "FDA"
    },
    {
      "type": "Microbe",
      "name": "May 2011"
    },
    {
      "type": "Microbe",
      "name": "no fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "only fidaxomicin"
    },
    {
      "type": "Microbe",
      "name": "fidaxomic